GENE ONLINE|News &
Opinion
Blog

2021-08-07| Technology

Reversing Obesity: Cytokine Treatment Makes Obese Mice ‘Sweat Fat’, UPenn Study Finds

by Isha Kapoor
Share To

In a seemingly remarkable discovery for treating Type 2 diabetes and combating insulin resistance, a team of researchers from Perelman School of Medicine, University of Pennsylvania serendipitously discovered that treating obese mice with a cytokine Thymic Stromal Lymphopoietin (TSLP) resulted in a significant loss of visceral fat- white adipose tissue (WAT) in 4 weeks.

Obesity and its associated complications such as Type 2 diabetes, chronic heart diseases, stroke, fatty liver disease, and certain cancers are serious global concerns. Despite public health initiatives, obesity rates are increasing alarmingly. WHO reports that typically more than 4 million people die each year due to being overweight or obese, according to the global disease burden.

Thus, under the pressing need to identify pathways that affect overweight and obesity, researchers from UPenn published their findings in Science. The team of investigators demonstrated that overexpression of TSLP causes significant loss of WAT via induction of skin T cell migration and increased sebum hypersecretion.

 

Overexpression of TSLP Reverses Obesity

TSLP is a cytokine- a type of immune system protein widely known to play a pivotal role in allergic inflammation and activation of numerous immune cell types. Additionally, the authors demonstrated that TSLP and T cells homeostatically regulate sebum production and skin anti-microbial peptides (AMP) expression, uncovering an intriguing role for the adaptive immune system in maintaining skin barrier function. 

Based on the immune regulatory function of TSLP, the researchers initially hypothesized to investigate the role of TSLP in correcting Type 2 diabetes via impacting insulin resistance. However, serendipitously they showed how the immune system could be targeted to reverse obesity.

The researchers delivered tslp-expressing adeno-associated virus (AAV) to obese mice that resulted in increased production of bodies’ TSLP levels. After four weeks, they discovered that overexpression of TSLP cytokine not only reduced the risk of developing insulin resistance, Type 2 diabetes, nonalcoholic steatohepatitis but also reversed the obesity, which were fed a high-fat diet, as evident by their decrease in weight from 45 grams to a healthy 25 grams. 

Notably, these mice also displayed selective loss of WAT-whose accumulation increases the risk of heart diseases, stroke, including others. Unexpectedly, the tslp-treated mice displayed an increased appetite, similar energy expenditure, and basal metabolism compared to untreated mice.

 

Sweating Fat Out

In order to explain the weight loss in tslp-treated mice, the authors noted a very seemingly unremarkable observation- ‘greasy fur’- a sign that indicated that the mice were sweating out fat from their skin. They discovered that the shiny fur of the tslp-treated mice is enriched with sebum- calorie-dense secretions from the sebaceous glands in the skin.

They showed that the release of sebum through the skin results in TSLP-induced WAT loss. Further, in order to prove the clinical relevance of their findings, the authors demonstrated that TSLP expression is significantly and positively correlated with sebaceous gland gene expression in healthy human skin.

Thus, the authors suggested that it is feasible that the selective loss of WAT could be achieved by sweating fat in humans by therapeutically shifting sebum release into high gear. Strikingly, these findings also give hope in combating liver diseases as the authors suggested in the paper that “diverting lipids toward the skin and away from the liver could also lead to improvement of obesity-associated non-alcoholic fatty liver disease (NAFLD), and nonalcoholic steatohepatitis (NASH).”

In conclusion, translating these findings into potential novel therapies would prove valuable in reversing obesity/ overweight and combating chronic liver diseases or lipid-associated disorders by hijacking the system that mobilizes unhealthy fat to the skin and increases sebum production/ secretion to induce fat loss.

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Wegovy Expands Its Reach: First Weight-Loss Medication Approved to Reduce Cardiovascular Risk
2024-03-11
Obesity Hope or Hype: Leveraging the Efficacy of Mainstream Weight Loss Pills (Second Part)
2024-03-07
M&A
GSK Completed the Acquisition of Aiolos Bio, Enhancing the Respiratory Portfolio of Asthma
2024-02-16
LATEST
Mechanisms of Allograft Rejection: Insights from Behind the Scenes
2024-04-25
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
Ochre Bio Announces Partnership with Boehringer Ingelheim to Develop Novel Regenerative Treatments for Patients with Advanced Liver Disease
2024-04-22
Earth Day Awareness: Hospitals Embrace Sustainability Efforts
2024-04-22
WHO Raises Alarm: Bird Flu Threat to Humans an ‘Enormous Concern’
2024-04-19
The Legal Battlefield of Weight-Loss Drugs: Eli Lilly and Novo Nordisk on the Defensive
2024-04-18
EVENT
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115
Scroll to Top